Encorafenib,Binimetinib
ono pharma,pierre fabre,pfizer
['columbus', 'columbus-ad']
head over to hall a at 1:15pm cdt to see paul lorigan's ( , ) work on the columbus-ad study design being presented. #asco23: #crukfunded
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK